Mongkol Lao-Araya

Dr. Mongkol Lao-Araya

Pediatrics, Faculty of Medicine Chiang Mai University, Chiang Mai, Thailand
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Immunity
Verified
Journal Article
Closed access
KGKorneliusz Golebski
Korneliusz Golebski
JLJanice A. Layhadi
Janice A. Layhadi
USUmit Sahiner
Umit Sahiner
ESEsther H. Steveling-Klein
Esther H. Steveling-Klein
MLMadison M. Lenormand
Madison M. Lenormand
MSMohamed H. Shamji
Mohamed H. Shamji

1 November 2014 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
MLMongkol Lao-Araya
Mongkol Lao-Araya
ESEsther Steveling
Esther Steveling
GSGuy W. Scadding
Guy W. Scadding
SDStephen R. Durham
Stephen R. Durham
MSMohamed H. Shamji
Mohamed H. Shamji

14 March 2015 in Allergy
Verified
Journal Article
Open access
PDF file
GSG. W. Scadding
G. W. Scadding
AEA. O. Eifan
A. O. Eifan
MLMongkol Lao-Araya
Mongkol Lao-Araya
MPM. Penagos
M. Penagos
SPS. Y. Poon
S. Y. Poon
SDS. R. Durham
S. R. Durham
Rationale Nasal allergen provocations may be useful in investigating the pathophysiology of allergic rhinitis and effects of treatments. Objective To use grass pollen nasal allergen challenge (NAC) to investigate the effects of allergen immunotherapy in a cross‐sectional study. Methods We studied nasal and cutaneous responses in untreated subjects with seasonal grass‐pollen allergic rhinitis (n = 14) compared with immunotherapy‐treated allergics (n = 14), plus a nonatopic control group (n = 14). Volunteers underwent a standardized NAC with 2000 biological units of timothy grass allergen (equivalent to 1.3 μg major allergen, Phl p5). Nasal fluid was collected and analysed by ImmunoCAP and multiplex assays. Clinical response was assessed by symptom scores and peak nasal inspiratory flow (PNIF). Cutaneous response was measured by intradermal allergen injection. Retrospective seasonal symptom questionnaires were also completed. Results Immunotherapy‐treated patients had lower symptom scores (P = 0.04) and higher PNIF (P = 0.02) after challenge than untreated allergics. They had reduced early (P = 0.0007) and late (P < 0.0001) skin responses, and lower retrospective seasonal symptom scores (P < 0.0001). Compared to untreated allergics, immunotherapy‐treated patients had reduced nasal fluid concentrations of IL‐4, IL‐9 and eotaxin (all P < 0.05, 8 h level and/or area under the curve comparison), and trends for reduced IL‐13 (P = 0.07, area under the curve) and early‐phase tryptase levels (P = 0.06). Conclusions Nasal allergen challenge is sensitive in the detection of clinical and biological effects of allergen immunotherapy and may be a useful surrogate marker of treatment efficacy in future studies.

14 December 2011 in Pediatrics International
Verified
Journal Article
Closed access
PDF file
MLMongkol Lao-Araya
Mongkol Lao-Araya
MTMuthita Trakultivakorn
Muthita Trakultivakorn

1 July 2007 in Vaccine
Verified
Journal Article
Closed access
MLMongkol Lao-Araya
Mongkol Lao-Araya
TPThanyawee Puthanakit
Thanyawee Puthanakit
LALinda Aurpibul
Linda Aurpibul
TSThira Sirisanthana
Thira Sirisanthana
VSVirat Sirisanthana
Virat Sirisanthana

15 June 2018 in Beneficial Microbes
Verified
Journal Article
Closed access
PKP. Kosuwon
P. Kosuwon
MLMongkol Lao-Araya
Mongkol Lao-Araya
SUS. Uthaisangsook
S. Uthaisangsook
CLC. Lay
C. Lay
JBJ. Bindels
J. Bindels
PCP. Chatchatee
P. Chatchatee
Little is known about the impact of nutrition on toddler gut microbiota. The plasticity of the toddler gut microbiota indicates that nutritional modulation beyond infancy could potentially impact its maturation. The objective of this study was to determine the effect of consuming Young Child Formula (YCF) supplemented with short chain galactooligosaccharides and long chain fructooligosaccharides (scGOS/lcFOS, ratio 9:1) andBifidobacterium breveM-16V on the development of the faecal microbiota in healthy toddlers. A cohort of 129 Thai children aged 1-3 years were included in a randomised controlled clinical study. The children were assigned to receive either YCF with 0.95 g/100 ml of scGOS/lcFOS and 1.8×107cfu/g ofB. breveM-16V (Active-YCF) or Control-YCF for 12 weeks. The composition and metabolic activity of the faecal microbiota, and the level of secretory immunoglobulin A were determined in the stool samples. The consumption of Active-YCF increased the proportion ofBifidobacterium(mean 27.3% at baseline to 33.3%, at week 12,P=0.012) with a difference in change from baseline at week 12 between the Active and Control of 7.48% (P=0.030). The consumption of Active-YCF was accompanied with a more acidic intestinal milieu compared to the Control-YCF. The pH value decreased statistically significantly in the Active-YCF group from a median of 7.05 at baseline to 6.79 at week 12 (P<0.001). The consumption of Active-YCF was associated with a softer pudding-like stool consistency compared to the Control-YCF. At week 6 and week 12, the between-group difference in stool consistency was statistically significant (P=0.004 andP<0.001, respectively). A Young Child Formula supplemented with scGOS/lcFOS andB. breveM-16V positively influences the development of the faecal microbiota in healthy toddlers by supporting higher levels ofBifidobacterium. The synbiotic supplementation is also accompanied with a more acidic intestinal milieu and softer stools.